State of New Jersey Common Pension Fund D Buys New Shares in Kiniksa Pharmaceuticals International, plc $KNSA

State of New Jersey Common Pension Fund D bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,871 shares of the company’s stock, valued at approximately $490,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Amundi bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Creative Planning bought a new position in Kiniksa Pharmaceuticals International in the second quarter worth $358,000. Finally, Quantbot Technologies LP bought a new position in Kiniksa Pharmaceuticals International in the second quarter worth $43,000. 53.95% of the stock is currently owned by institutional investors.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 655,991 shares of company stock worth $34,167,123 over the last ninety days. Corporate insiders own 53.48% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on KNSA shares. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Finally, Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $58.37 on Tuesday. The business’s fifty day moving average price is $47.67 and its two-hundred day moving average price is $43.86. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $59.75. The stock has a market capitalization of $4.49 billion, a price-to-earnings ratio of 64.86 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. During the same period last year, the business earned $0.11 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.